Soligenix stock analysis
Soligenix (0A6I) Share Price & Analysis
0A6I Stock Chart & Stats
- Day’s Range
- $0.32 - $0.33
- 52-Week Range
- $0.28 - $1.65
- Previous Close
- $0.32
- Volume
- N/A
- Average Volume (3M)
- 4,305
- Market Cap
- $7.50M
- Enterprise Value
- -$732.17K
- Total Cash (Recent Filing)
- $9.02M
- Total Debt (Recent Filing)
- $273.92K
- Price to Earnings (P/E)
- ―
- Beta
- -0.11
- Next Earnings
- Mar 30, 2027 (Est.)
- EPS Estimate
- -0.09
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Low Reported Leverage
Very low reported leverage reduces the immediate burden of debt service and preserves flexibility in capital allocation. Compared with a heavily indebted structure, this gives Soligenix more room to direct available resources toward development programs and operations.
Debt Reduction
Substantial debt reduction represents a durable improvement in the company’s financial structure and lowers exposure to refinancing pressure. If maintained, this cleaner balance sheet can reduce fixed obligations and improve resilience while the pipeline remains under development.
Modest Loss Reduction
A modest reduction in net loss provides a limited sign of improving cost discipline, even though profitability remains distant. Sustaining or extending this trend could slow the pace of capital consumption and improve the company’s ability to manage development spending over time.
Bears Say
Minimal Revenue And Persistent Losses
An effectively absent revenue base and persistent operating and net losses indicate that Soligenix has not yet established commercial earnings power. This leaves future financial performance dependent on successful development, regulatory progress, and eventual product commercialization.
Sustained Cash Burn
持续 negative operating and free cash flow shows that current activities are not self-funding. Ongoing cash burn can constrain investment in the pipeline and requires management to secure additional capital, making financial execution and funding access central to business continuity.
External Financing And Dilution Risk
Expanding the ATM program and authorized share count signals continued reliance on equity financing to support operations. Additional issuance can dilute existing holders, while the approved reverse-split range reflects ongoing capital-structure pressure rather than a self-sustaining business model.
Soligenix News
0A6I FAQ
What was Soligenix’s price range in the past 12 months?
What is Soligenix’s market cap?
When is Soligenix’s upcoming earnings report date?
How were Soligenix’s earnings last quarter?
Is Soligenix overvalued?
Does Soligenix pay dividends?
What is Soligenix’s EPS estimate?
How many shares outstanding does Soligenix have?
What happened to Soligenix’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Soligenix?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Soligenix
Soligenix, Inc., a biopharmaceutical firm in its advanced development stages, concentrates on bringing innovative products to market within the United States, specifically targeting rare illnesses. The company's operations are divided into two main divisions: Specialized BioTherapeutics and Public Health Solutions. Within the Specialized BioTherapeutics division, Soligenix is advancing SGX301 (marketed as HyBryte), a novel photodynamic treatment that has successfully completed its Phase III clinical trials for managing cutaneous T-cell lymphoma. This segment also includes SGX942, an innate defense regulator technology currently undergoing Phase III trials for various inflammatory conditions, notably oral mucositis in patients with head and neck cancer. Additionally, this division is pursuing proprietary oral formulations of beclomethasone 17,21-dipropionate designed to prevent or treat severe inflammatory gastrointestinal disorders, such as SGX203 for pediatric Crohn's disease. Another candidate, SGX302, is currently in Phase I/II clinical development for addressing mild-to-moderate psoriasis. The Public Health Solutions segment is dedicated to developing several critical assets. These include RiVax, a vaccine candidate against ricin toxin, which has successfully completed Phase Ia and Ib clinical evaluations; SGX943, a therapeutic agent in pre-clinical studies aimed at combating antibiotic-resistant and emerging infectious diseases; ThermoVax, an early-stage technology focused on enhancing vaccine thermostability; and CiVax, a pre-clinical vaccine candidate intended for COVID-19 prevention. Soligenix, Inc. was originally established as DOR BioPharma, Inc. before adopting its current name in 2009. Founded in 1987, the company maintains its corporate headquarters in Princeton, New Jersey.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Christopher J. Schaber
- Employees
- 14
- Website
- www.soligenix.com
- Address
- 29 Emmons Drive, Princeton, NJ, 08540, US
Soligenix (0A6I) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 6 | 2 | 14 |
| Technical Analysis | 6 | 2 | 2 |
| Moving Averages | 0 | 0 | 12 |














